Literature DB >> 29764932

Distribution of mast cell subtypes in interstitial cystitis: implications for novel diagnostic and therapeutic strategies?

Shabana T Malik1, Brian R Birch2, David Voegeli1, Mandy Fader1, Vipul Foria3, Alan J Cooper4, Andrew F Walls2, Bashir A Lwaleed1.   

Abstract

AIMS: To identify the presence and geographical distribution of mast cell (MC) subtypes: MCT (tryptase positive-chymase negative) and MCTC (tryptase positive-chymase positive) in bladder tissue.
METHODS: Bladder tissue was obtained from patients with painful bladder syndrome/interstitial cystitis (n=14) and normal histology from University Hospital Southampton tissue bank. Sequential tissue slices were immunohistochemically stained for MC subtypes using anti-MC tryptase (for MCT and MCTC) and anti-MC chymase (for MCTC). Stained sections were photographed, and positively stained MCs were quantified using ImageJ. Data were analysed using descriptive statistics and individual paired t-tests.
RESULTS: There was a significant difference in the density of MCs between each layer of the disease bladder, with the greatest accumulation within the detrusor (p<0.001). There was a significant increase in MCTC subtype in the lamina (p=0.009) in painful bladder syndrome/interstitial cystitis.
CONCLUSIONS: Our results suggest that mastocytosis is present within all layers of disease bladder, especially the muscle layer. The varying increase in MC subtypes in the lamina and mucosa may explain the variability in painful bladder syndrome/interstitial cystitis symptoms. A high influx of MCTC in the mucosa of individuals who also had ulceration noted within their diagnostic notes may be of the Hunner's ulcer subclassification. These findings suggest a relationship between the pathogenesis of MC subtypes and the clinical presentation of painful bladder syndrome/interstitial cystitis. A cohort study would further elucidate the diagnostic and/or therapeutic potential of MCs in patients with painful bladder syndrome/interstitial cystitis. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  cystitis; inflammation; mast cell; painful bladder

Mesh:

Substances:

Year:  2018        PMID: 29764932     DOI: 10.1136/jclinpath-2017-204881

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  6 in total

1.  Very Severe and Refractory Noninfectious Cystitis in Patients with Systemic Lupus Erythematosus: Potential Role of Rituximab Therapy.

Authors:  Vanessa Ocampo-Piraquive; Inés Mondragón-Lenis; Juan G De Los Rios; Carlos A Cañas
Journal:  Case Rep Rheumatol       Date:  2021-02-27

2.  The NLRP3 Inflammasome Inhibitor Dapansutrile Attenuates Cyclophosphamide-Induced Interstitial Cystitis.

Authors:  Sonia Kiran; Ahmed Rakib; Udai P Singh
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

3.  Bruton tyrosine kinase (BTK) may be a potential therapeutic target for interstitial cystitis/bladder pain syndrome.

Authors:  Guang Wang; Tong-Xin Yang; Jiong-Ming Li; Zi-Ye Huang; Wen-Bo Yang; Pei Li; Da-Lin He
Journal:  Aging (Albany NY)       Date:  2022-09-05       Impact factor: 5.955

4.  Micronized Palmitoylethanolamide-Polydatin Reduces the Painful Symptomatology in Patients with Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  M Cervigni; L Nasta; C Schievano; N Lampropoulou; E Ostardo
Journal:  Biomed Res Int       Date:  2019-11-11       Impact factor: 3.411

5.  Does cystoscopy method affect the investigation of bladder pain syndrome/interstitial cystitis?

Authors:  Visha K Tailor; Ellen Morris; Alka A Bhide; Ruwan Fernando; Guiseppe A Digesu; Vik Khullar
Journal:  Int Urogynecol J       Date:  2020-09-21       Impact factor: 2.894

6.  Differential Expression of microRNAs Correlates With the Severity of Experimental Autoimmune Cystitis.

Authors:  Vijay Kumar; Sonia Kiran; Haidar A Shamran; Udai P Singh
Journal:  Front Immunol       Date:  2021-07-14       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.